This is a type of breast cancer that starts in the milk ducts. It's called noninfiltrating because the cancer cells haven't spread into the surrounding breast tissue yet. It's considered a pre-cancerous condition.
Every report comes from a Lived member, sent anonymously.
Have you had Lumpectomy for DCIS (Ductal Carcinoma in Situ)?
Ductal carcinoma in situ (DCIS) is a condition in which abnormal cells grow in the lining of the breast's milk ducts but have not broken through the duct wall into the surrounding breast tissue. "In situ" means "in its original place." Because the cells are still contained, DCIS is called noninvasive or stage 0 breast cancer, and in this form it does not spread to lymph nodes or other parts of the body. DCIS matters because some cases, left alone, can change and grow through the duct wall to become invasive breast cancer, which can spread. Not every DCIS will do this, and some never would, but there is currently no reliable way to tell which ones will. Sources differ on the label: some describe DCIS as the earliest form of breast cancer, while the National Cancer Institute calls it a precancer. Either way, it is treated seriously, and the outlook is excellent. DCIS makes up roughly one in five new breast cancer diagnoses in the United States. Most people have no symptoms; it is usually found on a routine screening mammogram. It is different from atypical ductal hyperplasia (ADH), a noncancerous biopsy finding of unusual-looking duct cells that raises future breast cancer risk and is managed differently.
DCIS develops when cells lining a milk duct acquire changes in their genetic material (DNA) that make them grow abnormally. Usually the reason those changes happen in a particular person is not known. DCIS shares its risk factors with breast cancer in general. Risk rises with age and is higher in people with a personal or family history of breast cancer, inherited gene changes such as BRCA1 or BRCA2, a past biopsy showing certain benign changes (including atypical hyperplasia), or dense breast tissue. Longer lifetime exposure to estrogen also plays a part: starting periods early, reaching menopause late, having a first child later or not having children, and using menopausal hormone therapy. Past radiation to the chest, obesity and drinking alcohol add to risk as well. These are associations, not causes. Many people with DCIS have none of them, and most people with them never develop it. DCIS has become far more commonly diagnosed since screening mammography became widespread, largely because mammograms find small areas that would once have gone unnoticed.
DCIS rarely forms a lump that can be felt. More than 90% of cases are found by mammography alone, often as clusters of tiny calcium deposits (calcifications) that show up as white specks on the image. Occasionally DCIS causes a breast lump or a nipple discharge, sometimes bloody, from one breast. When a screening mammogram shows something suspicious, the next steps are usually more detailed mammogram views and sometimes an ultrasound or MRI. Only a biopsy can confirm DCIS. A small sample of tissue, usually taken with a needle, is examined under a microscope by a pathologist. The report answers three important questions. First, whether the cells are confined to the ducts (DCIS) or have started to invade nearby tissue (invasive cancer). Second, the grade, which describes how abnormal the cells look: low-grade (grade 1) DCIS tends to grow slowly, while high-grade (grade 3) DCIS, especially with dead cells in the center of the ducts (called comedo necrosis), is more likely to come back or to have invasive cancer nearby. Third, whether the cells have hormone receptors, meaning they use estrogen or progesterone to grow. Hormone receptor-positive DCIS can be treated with hormone-blocking medicine. Because a needle samples only part of the area, the full extent of DCIS, and whether any invasive cancer is hiding within it, is often clear only after surgery removes the whole area.
Nearly everyone with DCIS is offered treatment, because doctors cannot yet predict which cases would become invasive. The goal is to remove the abnormal area completely and lower the chance of DCIS or invasive cancer returning in the breast. Most people can choose between two kinds of surgery. Breast-conserving surgery (lumpectomy) removes the DCIS with a rim of normal tissue around it; the surgeon aims for clear margins, meaning no abnormal cells at the edge of the removed tissue, and a second operation is sometimes needed to achieve this. Lumpectomy is usually followed by a course of radiation therapy to the breast, which roughly halves the chance of DCIS or invasive cancer coming back in that breast. A simple mastectomy removes the whole breast and is often recommended when DCIS is large, is in several separate areas or cannot be cleared with lumpectomy; most people who have a mastectomy for DCIS do not need radiation, and breast reconstruction can be done at the same time or later. Lumpectomy keeps most of the breast but usually means radiation and a slightly higher chance of the problem returning in that breast. Long-term survival is very high with either approach. A surgeon may also remove the first lymph node in the armpit (sentinel lymph node biopsy), mainly with mastectomy or when invasive cancer is suspected, since it cannot be done easily afterward. For hormone receptor-positive DCIS, hormone therapy taken as a daily pill for about five years can further lower the chance of a new DCIS or invasive cancer in either breast. Tamoxifen, which blocks estrogen's effect on breast cells, can be used before or after menopause. Aromatase inhibitors such as anastrozole or exemestane, which lower the body's estrogen, are options after menopause. Common side effects include hot flashes; tamoxifen can also cause vaginal discharge and slightly raises the risk of blood clots and uterine cancer, while aromatase inhibitors often cause joint pain and bone thinning. Radiation and hormone therapy reduce recurrence, but trials have not shown that they help people live longer. That is why some people at lower risk, such as older adults or those with a small, low-grade area removed with wide clear margins, discuss whether to skip radiation or hormone therapy. Researchers are also studying active monitoring for low-risk DCIS: regular imaging and exams instead of immediate surgery. In a large US trial of women 40 and older with low- or intermediate-grade, hormone receptor-positive DCIS, active monitoring did not lead to more invasive cancer in the same breast after two years, but longer-term results are still awaited and it is not yet standard care.
The outlook after DCIS is excellent. More than 98% of people diagnosed are alive five years later, most are cured, and DCIS is less likely to come back than invasive breast cancer. When it does return, it may come back as DCIS or as invasive cancer, most often in the same breast, which is why follow-up matters. Recovery is generally quicker after lumpectomy than after mastectomy, particularly mastectomy with reconstruction, though lumpectomy usually adds a course of radiation. People taking hormone therapy usually do so for about five years, and side effects such as hot flashes or joint aches can often be managed or addressed by switching medicines. After treatment, follow-up visits typically come every few months at first and then become less frequent, about yearly after five years. After lumpectomy, a mammogram is usually done 6 to 12 months after finishing treatment and then at least every year. After mastectomy, the remaining breast is still checked with yearly mammograms. Many people find that worry about recurrence is the hardest part of a diagnosis that is, medically, very treatable; support groups and clear information from the care team can help.
Make an appointment if you notice a new breast lump, nipple discharge from one breast (especially bloody), or a change in the size, shape or skin of a breast, whether or not you have had DCIS. If a screening mammogram calls you back for more images, complete those tests promptly. After treatment, report any new change in either breast or the surgical area rather than waiting for the next scheduled visit. If you take tamoxifen, contact your care team right away about unusual vaginal bleeding or spotting, or about pain, redness or swelling in one calf, shortness of breath or chest pain, which can signal a blood clot.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with DCIS (Ductal Carcinoma in Situ) is like, what's helped you, or ask the community a question.